Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
16740970
DOI
10.1210/en.2005-1624
PII: en.2005-1624
Knihovny.cz E-zdroje
- MeSH
- adiponektin krev genetika MeSH
- dieta MeSH
- dietní sacharidy aplikace a dávkování MeSH
- exprese genu účinky léků MeSH
- fenofibrát aplikace a dávkování MeSH
- glykemický clamp MeSH
- hmotnostní úbytek účinky léků MeSH
- inzulin krev farmakologie MeSH
- inzulinová rezistence * MeSH
- játra chemie účinky léků MeSH
- kosterní svaly chemie MeSH
- krevní glukóza analýza MeSH
- kyseliny mastné neesterifikované analýza MeSH
- lipidy biosyntéza MeSH
- messenger RNA analýza MeSH
- myši inbrední C57BL MeSH
- myši MeSH
- obezita krev etiologie patofyziologie MeSH
- PPAR alfa agonisté fyziologie MeSH
- receptory adiponektinu MeSH
- receptory buněčného povrchu genetika MeSH
- resistin krev genetika MeSH
- triglyceridy krev MeSH
- tuková tkáň chemie patologie MeSH
- velikost orgánu účinky léků MeSH
- ztučnělá játra krev farmakoterapie etiologie MeSH
- zvířata MeSH
- Check Tag
- mužské pohlaví MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- adiponectin receptor 1, mouse MeSH Prohlížeč
- adiponectin receptor 2, mouse MeSH Prohlížeč
- adiponektin MeSH
- dietní sacharidy MeSH
- fenofibrát MeSH
- inzulin MeSH
- krevní glukóza MeSH
- kyseliny mastné neesterifikované MeSH
- lipidy MeSH
- messenger RNA MeSH
- PPAR alfa MeSH
- receptory adiponektinu MeSH
- receptory buněčného povrchu MeSH
- resistin MeSH
- triglyceridy MeSH
We studied the effect of peroxisome proliferator-activated receptor-alpha (PPAR-alpha) activation on serum concentrations and tissue expression of resistin, adiponectin, and adiponectin receptor-1 and -2 (AdipoR1 and AdipoR2) mRNA in normal mice and mice with insulin resistance induced by lipogenic, simple-carbohydrate diet (LD). Sixteen weeks of LD feeding induced obesity with liver steatosis and increased insulin levels but did not significantly affect circulating adiponectin or resistin. Treatment with PPAR-alpha agonist fenofibrate decreased body weight and fat pad weight and ameliorated liver steatosis in LD-fed mice with concomitant reduction in blood glucose, free fatty acid, triglyceride, serum insulin levels, and homeostasis model assessment index values. Euglycemic-hyperinsulinemic clamp demonstrated the development of whole-body and liver insulin resistance in LD-fed mice, which were both normalized by fenofibrate. Fenofibrate treatment markedly increased circulating resistin levels on both diets and adiponectin levels in chow-fed mice only. Fat adiponectin mRNA expression was not affected by fenofibrate treatment. Resistin mRNA expression increased in subcutaneous but not gonadal fat after fenofibrate treatment. In addition to fat, a significant amount of adiponectin mRNA was also expressed in the muscle. This expression markedly increased after fenofibrate treatment in chow- but not in LD-fed mice. Adipose tissue expression of AdipoR1 mRNA was significantly reduced in LD-fed mice and increased after fenofibrate treatment. In conclusion, PPAR-alpha activation ameliorated the development of insulin resistance in LD-fed mice despite a major increase in serum resistin levels. This effect could be partially explained by increased AdipoR1 expression in adipose tissue after fenofibrate treatment.
Citace poskytuje Crossref.org